International Clinical Trial: A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468851) titled 'A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy' on March 8.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Condition: High-risk Non-muscle-invasive Bladder Cancer

Intervention: Drug: HS-10566 Drug: HS-10566

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: June 10, 2026

Target Sample Size: 180

Countries of Rec...